文献速递癫痫

脑损伤后癫痫患者癫痫发生过程中的共同通路:系统综述与Meta分析的研究发现

Common Pathways of Epileptogenesis in Patients With Epilepsy Post-Brain Injury: Findings From a Systematic Review and Meta-analysis.
PubMed 文献 · Neurology · 2023-11-27

该系统综述与Meta分析检索至2022年1月25日的文献,纳入22项研究(1499例脑损伤后癫痫患者和7929例对照),评估血液或脑脊液生物标志物与脑损伤后癫痫风险的关联。19种标志物可进行Meta分析,其中4项研究的血糖水平在卒中后癫痫患者中显著高于无卒中后癫痫者(SMD 0.44;CI 0.19-0.69)。由于方法学异质性、偏倚和验证不足,目前不能推荐使用所报道的生物标志物设计抗癫痫发生试验或用于临床。

要点

  • 4项研究显示卒中后癫痫患者血糖显著高于无卒中后癫痫者(SMD 0.44;CI 0.19-0.69)。
  • 22项研究中21项存在中至高偏倚风险,仅9项提供验证数据。
  • 由于方法学异质性和验证不足,目前不能推荐所报道的生物标志物用于临床或试验设计。

核心结论

  • 由于方法学异质性、纳入研究的偏倚和验证研究不足,目前不能推荐使用所报道的生物标志物设计抗癫痫发生试验或用于临床。
  • 分析提示炎症在癫痫发生中可能起作用,但这可能不是唯一机制。
  • 应开展设计严谨、方法为监管机构所接受的生物标志物研究。

研究设计与样本

  • 系统综述与Meta分析,检索MEDLINE、Embase、PsycInfo、Web of Science和Cochrane至2022年1月25日。
  • 纳入22项研究,含1499例脑损伤后癫痫患者和7929例无脑损伤后癫痫对照。
  • 主要结局为有无脑损伤后癫痫患者平均生物标志物水平的差异,计算汇总标准化均数差(SMD)及95%CI,并进行分子互作网络与富集分析(PROSPERO CRD42021297110)。

主要发现

  • 共研究45种血液或脑脊液生物标志物,样本采集时间点各异。
  • 45种标志物中28种仅在单一研究中 investigated,仅9种提供验证数据,早发型和晚发型癫痫定义不一。
  • 19种标志物可进行Meta分析;4项研究中卒中后癫痫患者血糖显著高于无卒中后癫痫者(SMD 0.44;CI 0.19-0.69)。
  • 个体研究中,15种血液标志物和7种脑脊液标志物与脑损伤后癫痫显著相关。
  • 富集分析显示显著标志物(白细胞介素[IL]-6、IL-1β)主要与炎症相关。

临床怎么用

  • 由于方法学异质性、偏倚和验证不足,目前不能推荐使用所报道的生物标志物设计抗癫痫发生试验或用于临床。

局限性

  • 22项研究中21项存在中至高偏倚风险。
  • 45种标志物中28种仅在单一研究中 investigated,仅9种提供验证数据。
  • 研究对早发型和晚发型癫痫使用不同定义。
  • 样本采集时间点各异。
  • 方法学异质性和纳入研究的偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Epilepsy may result from various brain injuries, including stroke (ischemic and hemorrhagic), traumatic brain injury, and infections. Identifying shared common biological pathways and biomarkers of the epileptogenic process initiated by the different injuries may lead to novel targets for preventing the development of epilepsy. We systematically reviewed biofluid biomarkers to test their association with the risk of post-brain injury epilepsy. METHODS: We searched articles until January 25, 2022, in MEDLINE, Embase, PsycInfo, Web of Science, and Cochrane. The primary outcome was the difference in mean biomarker levels in patients with and without post-brain injury epilepsy. We used the modified quality score on prognostic studies for risk of bias assessment. We calculated each biomarker's pooled standardized mean difference (SMD) and 95% CI. Molecular interaction network and enrichment analyses were conducted in Cytoscape (PROSPERO CRD42021297110). RESULTS: We included 22 studies with 1,499 cases with post-brain injury epilepsy and 7,929 controls without post-brain injury epilepsy. Forty-five biomarkers in the blood or CSF were investigated with samples collected at disparate time points. Of 22 studies, 21 had a moderate-to-high risk of bias. Most of the biomarkers (28/45) were investigated in single studies; only 9 provided validation data, and studies used variable definitions for early-onset and late-onset seizures. A meta-analysis was possible for 19 biomarkers. Blood glucose levels in 4 studies were significantly higher in patients with poststroke epilepsy (PSE) than those without PSE (SMD 0.44; CI 0.19-0.69). From individual studies, 15 biomarkers in the blood and 7 in the CSF were significantly associated with post-brain injury epilepsy. Enrichment analysis identified that the significant biomarkers (interleukin [IL]-6, IL-1β]) were predominantly inflammation related. DISCUSSION: We cannot yet recommend using the reported biomarkers for designing antiepileptogenesis trials or use in the clinical setting because of methodological heterogeneity, bias in the included studies, and insufficient validation studies. Although our analyses indicate the plausible role of inflammation in epileptogenesis, this is likely not the only mechanism. For example, an individual's genetic susceptibilities might contribute to his/her risk of epileptogenesis after brain injury. Rigorously designed biomarker studies with methods acceptable to the regulatory bodies should be conducted.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Misra S, Khan EI, Lam TT, et al. Common Pathways of Epileptogenesis in Patients With Epilepsy Post-Brain Injury: Findings From a Systematic Review and Meta-analysis. Neurology. 2023. PMID: 37550071. doi:10.1212/WNL.0000000000207749

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。